CTRI/2024/07/071040Not yet recruitingPhase 3
The Efficacy Of Gabapentin For Chronic Intractable CoughIn Interstitial Lung Disease - A Single Centre, Open-label,Randomized Controlled Trial - NI
Trial Snapshot
- Phase
- Phase 3
- Status
- Not yet recruiting
- Sponsor
- one
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients aged 18 years to 70 years of age. Individuals classified with interstitial lung disease according to the most recent diagnostic criteria established by the American Thoracic Society. Patients with chronic intractable cough, that is cough more than eight weeks with a severity of more than 40mm on VAS score. Patients with no contraindications to Gabapentin treatment
Exclusion Criteria
- •Patients who give negative informed consent. Patients with exposure to Gabapentin or Pregabalin within 2 months. Upper respiratory tract infection within 2 months. Current or ex-smokers. Patients presenting with acute exacerbation of ILD. Patients with co-morbidities like Obstructive airway disease, Gastroesophageal reflux disease or Congestive Cardiac Failure.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease - GABATAXEUCTR2008-005167-33-DECharité University Medicine Berlin
Completed
Phase 2
The efficacy of Gabapentin in the management of post menopausal sleep disorder and life qualitySleep disturbance.Nonorganic sleep disordersIRCT201304184686N3Arak University Medical of Sciences270
Completed
Phase 2
Prevention of Chemotherapy Induced Neuropathychemotherapy induced neuropathy.Other antineoplastic drugsIRCT2017021132494N1Bakhtar Bioshimi Company40
Completed
Not Applicable
A study to evaluate the usefulness of drug Gabapentin in reducing adverse symptoms after brain injuryCTRI/2020/04/024537DR SURUCHI60
Recruiting
Phase 2
Evaluation of the effect of Gabapentin in patients with myocardial infarctioIRCT20220516054874N2Mashhad University of Medical Sciences68